Clinical Research Directory
Browse clinical research sites, groups, and studies.
Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients
Sponsor: Ain Shams University
Summary
Kidneys have a vital role in glucose homeostasis by various mechanisms, one of the major mechanisms is through SGLT2. This role was commonly overlooked till development of the new SGLT2 inhibitors. (Ni, L., et al 2020) The SGLT2 inhibitor class of glucose-lowering agents has recently shown beneficial effects to reduce the onset and progression of renal complications in people with and without diabetes, through slow the decline in glomerular filtration rate (GFR), delaying the onset of microalbuminuria and slow or reverse the progression of proteinuria. (Nespoux, J., \& Vallon, V. 2020) The drug pentoxifylline is a methyl-xanthine derivative and a nonselective phosphodiesterase inhibitor with anti-inflammatory, antiproliferative and antifibrotic actions currently indicated for peripheral artery disease. (Panchapakesan U et al.,2018) Chronic kidney disease is a progressive disorder in which patients are treated according to complications presented such as hypocalcemia, hyperkalemia, anemia and metabolic acidosis.
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
210
Start Date
2024-03-01
Completion Date
2025-07
Last Updated
2024-05-20
Healthy Volunteers
No
Conditions
Interventions
Dapagliflozin 10mg Tab
Patients will be given dapagliflozin 10 mg once daily
Pentoxifylline 400 MG
Patients will be given pentoxyifylline 400 mg twice daily
Locations (1)
Ain Shams University
Cairo, Egypt